Clinical trials: Solid Malignant Tumor
Solid Tumor, Adult, BRCA1 Mutation
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
- Conditions
- Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- NCT06380660
- Testing
- ACE-86225106 tablet
- Where
- 14 sites in China
- Volunteers
- 298 people
- Sponsor
- Acerand Therapeutics (Shanghai) Limited
Solid Tumor
PET Study With [89Zr]-Df-CriPec® Docetaxel
A clinical phase I, open-label PET study with [89Zr]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of [89Zr]-Df-CriPec® docetaxel.
- Trial name
- NCT03712423
- Testing
- Cripec Docetaxel
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Amsterdam UMC, location VUmc
Cancer Survivor, Unspecified Adult Solid Tumor, Protocol Specific
Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke
RATIONALE: Contingency management is a behavioral treatment approach that provides immediate rewards for positive change in behavior such as quitting smoking.
- Trial name
- NCT00079469
- Testing
- smoking cessation intervention, bupropion hydrochloride
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor, Metastatic Solid Tumor
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
- Conditions
- Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT05678010
- Testing
- AZD1390, Stereotactic Body Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma, Neuroblastoma
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Background: Pazopanib, a drug that inhibits the growth of new blood vessels in tumors, was recently approved by the Food and Drug Administration to treat advanced kidney cancer in adults.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT01130623
- Testing
- Pazopanib (GW786034)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Malignant Solid Tumor
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect…
- Trial name
- NCT00836888
- Testing
- ONO-4538
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumor
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
This is a phase 1, open-label, single-arm study in Chinese patients with unresectable, locally advanced or metastatic solid tumor with KRAS G12C mutation, for which treatment with curative intent is not available.
- Trial name
- NCT05263986
- Testing
- MRTX849
- Where
- 8 sites in China
- Volunteers
- 22 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Advanced Solid Tumors
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.
- Trial name
- NCT06770569
- Testing
- HRS-3802
- Where
- 6 sites in Australia, China
- Volunteers
- 100 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Levocarnitine in Treating Fatigue in Cancer Patients
RATIONALE: Levocarnitine may help improve energy levels in cancer patients. PURPOSE: This randomized phase III trial is studying how well levocarnitine works compared to a placebo in treating fatigue in cancer patients.
- Trial name
- NCT00091169
- Testing
- levocarnitine
- Where
- 116 sites in United States
- Volunteers
- 376 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Solid Cancers
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT00954642
- Testing
- bevacizumab, MNRP1685A, paclitaxel
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Advanced Malignant Solid Tumor
Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden
CAPTURE is a prospective, interventional, randomized, phase 2, double-blind, placebo-controlled study assessing the therapeutic add-on effect of the balanced THC/CBD extract (Cannabis extract Avextra 10/10 oral solution) on…
- Trial name
- CAPTURE (NCT07459920)
- Testing
- Cannabis Extract Oil
- Where
- Italy
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00296062
- Testing
- bevacizumab, capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Solid Tumor, Metastatic Tumor
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further…
- Conditions
- Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT03238027
- Testing
- Axatilimab, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Syndax Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
PR104 and G-CSF in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00616213
- Testing
- filgrastim, PR104, F-18-fluoromisonidazole
- Where
- 3 sites in United States, New Zealand
- Volunteers
- 5 people
- Sponsor
- Proacta, Incorporated
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Advanced/Metastatic Malignant Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 in patients with advanced/metastatic solid tumors.
- Trial name
- NCT06115642
- Testing
- HLX43, HLX10
- Where
- 14 sites in United States, China and 1 more
- Volunteers
- 367 people
- Sponsor
- Shanghai Henlius Biotech
Cancer
BRIDGE-SIC Efficacy Trial
This is a pragmatic, prospective, randomized clinical trial to test the effectiveness of large language model (LLM)-generated serious illness conversation (SIC) summaries delivered to patients' inpatient and outpatient clinicians…
- Trial name
- NCT07735442
- Testing
- LLM-generated SIC summary email to clinical teams
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumor
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.
- Trial name
- NCT05369286
- Testing
- "MAX-40279-01" and "Toripalimab"
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Maxinovel Pty., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00573690
- Testing
- carboplatin, cisplatin, etoposide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.